Great Lakes NeuroTechnologies has introduced the Kinesia ProView to visualise motor symptom severity response during programming of deep brain stimulation (DBS) for the treatment of Parkinson's disease (PD). Kinesia ProView provides a standardised platform to quantitatively assess how symptoms such as tremor, bradykinesia and dyskinesias change in response to specific DBS settings during out-patient programming procedures.
During a programming assessment, the patient wears a wireless sensor to assess above motor symptoms at each DBS setting. A tablet PC application creates colour-coded maps as the programming session progresses, which display specific symptom severities as a function of stimulation settings. These tuning maps allow physicians to visually assess the programming parameter space and optimise the final settings for specific symptoms and battery consumption. Once the programming session is complete, patient data and tuning maps are transmitted via broadband connectivity to a cloud-based server for storage, reporting and trending using the Kinesia web application. Developed in collaboration with clinical studies at the Cleveland Clinic and University of Minnesota, the system has regulatory approvals from the FDA, CE marking, Health Canada and Australia Therapeutic Goods Administration approval for distribution in international markets.
The system integrates a secure, HIPAA-compliant web application and a broadband enabled tablet interface with wireless patient sensors. Fuelled by funding support from the National Institutes of Health in the US, including the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, the Kinesia technology suite has been commercialised and clinically validated in a number of studies and with hundreds of patients.